Trial Profile
An Expanded Access Study of TAS-102 in Patients with Refractory Metastatic Colorectal Cancer
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 13 Jun 2017
Price :
$35
*
At a glance
- Drugs Tipiracil/trifluridine (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Expanded access; Therapeutic Use
- 13 Jun 2017 New trial record
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.